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||ABSTRACT
Background: Apart from functioning as a multimodal hematopoietic growth factor, granulocyte colony-stimulating factor
(G-CSF) causes intense consequences on the brain. It has been viewed that G-CSF boosts the improvement from the
neurologic deﬁcits in rodent models of central nervous system diseases. Aims and Objective: To evaluate the efﬁcacy of
G-CSF as an intervention for improving cognitive deﬁcits commonly associated with aging. Materials and Methods: In this
study, male Wistar rats aged 21 months were treated for 2 weeks with G-CSF intraperitoneally at doses of 10, 50, and
70 mg/kg/day. The learning process was assessed by the reference memory task in the Morris water maze, by comparing
the G-CSF–treated group with the control animals. All the rats received Morris water maze training (four trials/day for
5 days) in order to assess the hippocampal-dependent spatial learning and received a 60-s probe trial test of spatial memory
retention 24 h after the twentieth trial. Result: Over 5 days of training, G-CSF (10, 50, and70 mg/kg/day) signiﬁcantly
reduced the latency and path length to ﬁnding the escape platform (Po 0.01). In probe trials (without platform), on the last
day of training, the G-CSF–treated group spent signiﬁcantly longer time in the platform quadrant when compared with the
control animals (Po 0.01). Among the treated groups, the 50-mg/kg dosage of G-CSF induced the best rehearsals memory.
Conclusion: The ﬁndings observed in this study support G-CSF as a promising therapeutic aid for cognitive enhancement in
the aging phenomenon.
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||INTRODUCTION
Granulocyte colony-stimulating factor (G-CSF) is a member of
the cytokine family of growth factors. It acts as a potent
hematopoietic factor that enhances the survival and drives
differentiation of myeloid lineage cells, resulting in the
generation of neutrophilic granulocytes.[1] The endothelium,
macrophages, and several other immune cells are involved in
the formation of G-CSF. G-CSF and its receptor have also been
reported to be expressed in neurons and neural progenitor
cells that reside in the hippocampal neurogenic niche.[2] G-CSF
passes through the intact blood–brain barrier and possesses
putative neuroprotective properties thought to be related to its
anti-inﬂammatory effects and the ability to block neuronal
programmed cell death through the interactions with G-CSF
receptors.[3,4] G-CSF may also be a potent neuronal growth
factor. These properties make G-CSF a promising candidate for
treating cognitive impairment in the elderly persons. Cognitive
impairment and dementia are the common serious health
problems, which impair the quality of life in the elderly people.
It has been reported by various studies that, as the age of
humans increases, there is a steady decrease in the features
such as learning and memory.[5,6] Furthermore, owing to this
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deterioration associated with the aging process, deﬁcits in the
spatial learning and memory tasks occur.[7–11] These age-
related spatial learning and memory deﬁcits have been
attributed, in part, to the alterations in the connections and
function of hippocampal formation.[12,13] A previous study
indicated that G-CSF administration can reverse the cognitive
impairment in a commonly used Alzheimer disease mouse
model.[14] Accordingly, the G-CSF treatment improved the
spatial learning and reacquisition of information in rats engaged
in a radial maze, presumably, by promoting the survival of new
neurons[3]; in a murine model of pneumococcal meningitis,
G-CSF increased the hippocampal neurogenesis and improved
the spatial learning performance. For the cognitive beneﬁts of
G-CSF, multiple mechanisms, including reduction of inﬂamma-
tion, stimulation of neurogenesis and synaptogenesis, activation
of resident microglia, and the induction of phagocytosis have
been proposed.[14,15] However, G-CSF–driven memory recovery
in the elderly persons remains underexplored. This study
investigated the effects of G-CSF treatment in aged rats by using
behavioral parameters of cognitive performance in Morris
water maze (MWM).
||MATERIALS AND METHODS
Animals
Twenty-four-month-old rats weighing 400–450 g were obtained
from the Aging Farm, which was established at our animal
house and used as the aged rats. The aged rats were produced
by keeping them for 21 months in the Aging Farm after
purchase from the same breeder at an age of 3 months. They
were housed two per cage in a temperature (23 ± 1°C) and
light (12-h light/dark schedule; lights on at 8 a.m.)-controlled
environment and fed laboratory food and water ad libitum. All
the protocols for the experiments on animals were approved by
the Research and Ethics Committee of Golestan University of
Medical Sciences, Golestan, Iran. The animals were randomly
divided into four groups of eight animals each, including control
(C) (untreated) group, and 10-, 50-, and 70-mg/kg ﬁlgrastim
groups. Filgrastim was purchased from Ariatinagen Company
(Gorgan, Iran), and after dissolving in saline, administrated
intraperitoneally at doses of 10, 50, and 70 mg/kg to the rats
for 2 weeks. In the last week, the injections were administered
60 min before the MWM task.
MWM Task
A black circular pool (160 cm diameter, 60 cm high) ﬁlled with
water (30 cm depth) at 24± 2°C was utilized as the MWM for
the study. Four quadrants arbitrarily designed as northeast
(NE), northwest (NW), southeast (SE), and southwest (SW)
areas were segmented in the pool. One centimeter below the
water surface was concealed a submerged Plexiglas platform
(10 cm  10 cm) and placed in a particular place in the center
of the NW quadrant. The animals underwent 5 days of training
with the hidden platform; four training sessions with a 60-s
intersession interval were performed on each day. A rat was
kept with its face toward the wall of the pool at any one of the
three start points and the trial initiated. The start location was
varied on each training trial and changed each day. The trial
was terminated when the animal entered the platform. If the rat
did not ﬁnd the platform within 60 s, it was placed on the
platform by the experimenter for 15 s. During the acquisition of
the spatial navigation task, all the groups were given one
session of four trials each day (days 1–5; trials 1–20). Spatial
memory was evaluated in the probe trial. On the sixth day (trial
21), the platform was removed, and the animals were allowed
to swim for 60 s. By using a computerized video tracking
system (Maze router, Urmia Instruments, Inc.), the path of the
animals in the maze was observed. The parameters such as the
time taken to reach the platform (latency), swimming speed,
and swim path length (SPL) were determined in the training
trials. Moreover, during the probe trials, an estimation of the
percentage run time of each experimental animal within the
quadrant of the water bath where the hidden platform had been
placed in the training trials was done.
Statistical Analysis
Data were analyzed using SPSS software, version 11.5 and plotted
as mean ± SD. The comparison among the groups was made
using analysis of variance (ANOVA) with a post hoc Tukey test or
repeated-measures ANOVA. The results were considered signiﬁ-
cant when P o 0.05 and highly signiﬁcant when P o 0.01.
||RESULTS
Acquisition
The escape latency and the distance traveled by the rats to
ﬁnding the hidden platform in the water maze task are shown
in Figures 1A and 1B, respectively. Animals from all the groups
progressively improved their ability to ﬁnd the platform over
the 5 days of acquisition (P o 0.05). However, repeated-
measures ANOVA of these data revealed that the performance
on this task differed between the control and ﬁlgrastim-treated
groups in the trial days (P o 0.01). Inspection of the data in
these days showed that animals in ﬁlgrastim-treated groups
learned the task at a high rate, traveled a shorter distance, and
spent less time to ﬁnd the escape platform than the control
group (P o 0.01), but there was no signiﬁcant difference
observed in these data among the groups that received
ﬁlgrastim on each trial day. The analysis of swimming speed
by using two-way ANOVA also showed no signiﬁcant differ-
ences as the training days progressed among the groups and no
interaction between the days and the groups [Figure 2].
Probe Trial
By applying a different starting position, a 60-s free-swim probe
trial was carried out, and the retention of the spatial training
was assessed 24 h after the last training session. The
parameters such as the time spent in the quadrant containing
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the platform during the training (target quadrant) were
determined from the probe trial. Post hoc analysis showed that
the ﬁlgrastim-treated group was signiﬁcantly different from the
control (P o 0.01) group. The ﬁlgrastim-treated animals spent
more time in the training quadrant than the control animals in
the 60-s probe trial [Figure 2]. In addition, among the treated
groups the 50-mg/kg/day group was found to have spent more
time in the training quadrant (P o 0.01). Figure 3 shows the
representative plots (top view) of individual swim paths of one
rat for each treatment group and probe trial. In these examples,
the start location was in the NW quadrant of the pool, and the
platform had formerly been located in the NE quadrant of the
pool (indicated by small circle for illustration purposes only;
note that no platform was present in probe trials).
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Figure 1: Effects of short-time treatment with ﬁlgrastim (14 days) on the performance of spatial memory acquisition phase in MWM. Average
escape latency (A), distance traveled (B), and swimming speed (C) within each day (made up of four trials) are shown. Asterisks indicate a signiﬁcant
difference from the control group (**P o 0.01).
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||DISCUSSION
There are now several lines of evidence suggesting that G-CSF
possesses neuroprotective and anti-inﬂammatory effects in
various neurological disease models and can improve cognition
and memory. In this study, we examined the effects of G-CSF on
spatial memory in aged rats. The animals were treated for
2 weeks with different doses of ﬁlgrastim, and their performance
in a reference memory task—the water maze, was compared
with the vehicle-treated controls. The rats treated with 10, 50,
and 70 mg/kg/day of ﬁlgrastim performed signiﬁcantly better
than the control group in the water maze task. Latency and path
length to ﬁnding the escape platform signiﬁcantly reduced in
the ﬁlgrastim-treated animals. In a probe trial, where the
platform was removed from the pool, the ﬁlgrastim-treated
groups were also shown to spend signiﬁcantly longer time in
the platform quadrant than control animals, demonstrating a
better ability of remembering the position of the platform.
Among the ﬁlgrastim-treated groups, the 50-mg/kg dosage of
ﬁlgrastim induced the best rehearsals. In a similar study,
Sikoglu et al.[16] observed the immediate effects of G-CSF in
spatial memory recovery in a rat model of traumatic brain
injury. Our results also showed an immediate and beneﬁcial
effect of ﬁlgrastim on cognitive function. The mechanism of the
G-CSF memory enhancing is unknown. Previous studies on
intracerebral hemorrhage indicated that the beneﬁcial effect of
G-CSF on brain might be mediated through its anti-inﬂamma-
tory effect.[17] In addition, it is possible that G-CSF memory
enhancer effect was not global but impactful in the brain
regions involved in spatial learning.[18] G-CSF has been known
to exhibit antiapoptotic effects in mature neurons and activate
multiple cell survival pathways.[19] Both the G-CSF and its
receptors are widely expressed by neurons in the central
nervous system,[20] and G-CSF can activate the transcription
factor cAMP response element-binding protein (CREB) through
the mitogen-activated protein kinase pathway. The CREB plays
an important role for long-term potentiation, a cellular process
associated with learning and memory.[21] Accordingly, G-CSF
treatment improved spatial learning and reacquisition of
information in rats engaged in a radial maze, presumably, by
promoting the survival of new neurons,[22] which suggests an
autocrine protective signaling mechanism that can improve
memory in elderly people. We, therefore, propose G-CSF as a
potential new drug for enhancing memory in the elderly people.
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Figure 2: Mean ( ± SEM) percentage of the time spent in target quadrant in MWM during the probe trials. Asterisks indicate a signiﬁcant
difference from the control group (**P o 0.01).
Figure 3: Tracings of the typical swim patterns in the probe trials (trial 21) at the control (A), and 10- (B), 50- (C), and 70-mg/kg (D) ﬁlgrastim
groups tested. The escape platform was on the NW quadrant.
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||CONCLUSION
Daily IP injections of ﬁlgrastim at doses of 10, 50, and 70 mg/kg for
2 weeks improved aged rats’ performance in the MWM, and, hence,
although a low dose of 10 mg/kg can exert signiﬁcant memory
enhancer effect in old rats, a daily injection of 50 mg/kg ﬁlgrastim
showed a good spatial memory enhancing effect in the aged rats.
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